In this episode of Compliance is Cool, AmSpa founder Alex Thiersch and General Counsel Patrick O'Brien dive deep into the legislative "flurry" currently sweeping through the medical spa industry. Focusing on Indiana's Senate Bill 282, the duo explores how a seemingly benign licensing bill evolved into a restrictive piece of legislation targeting both medical spas and compounding pharmacies. They pull back the curtain on the "Big Pharma" influence—specifically Eli Lilly’s presence in Indianapolis—and explain why the sudden push to track compounded GLP-1 medications has created a "death by paperwork" scenario for med spa owners. This episode serves as a wake-up call for the industry as similar legislative language begins to surface in states like Florida, Iowa, and Arizona. Discussion points include: An overview of the path Indiana SB 282 took from draft to law An explanation of the bill's provisions and how they would adversely affect medical providers The connection between SB 282 and big pharma's battle with compounding medications How Alex, Patrick, and their lobbyist worked with legislators to improve the bill and what it still includes The national trends that practitioners should stay aware of, and how AmSpa and its members can be proactive in leading the conversation